The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
March 27, 2017
View Complete Issue         Table of Contents 2019 
Nusinersen (Spinraza) for Spinal Muscular Atrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nusinersen (Spinraza) for Spinal Muscular Atrophy
March 27, 2017 (Issue: 1517)
The FDA has approved nusinersen (Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births. It is the first drug to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nusinersen (Spinraza) for Spinal Muscular Atrophy
Article code: 1517b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.